FuboTV Gaining Popularity North America, High Growth In Paid Subscribers Show

FuboTV (NYSE: FUBO) reported strong Q124 results with sales up 24%, beating estimates. North America revenue up 24%, paid subscribers up 18%, and ARPU up 10%. Lawsuit against DIS, FOX, WBD remains. Q2 and FY24 revenue outlook revised upwards. FUBO stock up 11% at $1.72 premarket.

FuboTV Inc (NYSE:FUBO) shares soared in premarket by as much as 10% after the company reported fiscal first-quarter 2024 results. Sales grew 24.0% Y/Y to $402.4 million, beating the analyst consensus estimate of $381.3 million.

Adjusted EPS loss of $(0.11) beat the analyst consensus loss estimate of $(0.21).

The company’s gross margin stood at 7%, up by 588 bps Y/Y. 

North America Streaming: Revenue grew 24% Y/Y to $394 million as paid subscribers grew 18% Y/Y to 1.511 million. Average revenue per user (ARPU) rose 10% Y/Y to $84.54.

Rest of the World Streaming: Revenue was $8.4 million, a 7% Y/Y jump, with a paid subscriber growth of 5% Y/Y to 397,000. ARPU grew by 7% Y/Y to $7.

FuboTV held $175 million in cash and equivalents as of the first quarter 2024.

“Fubo’s first quarter 2024 performance builds upon the strong momentum achieved in the prior year, with double-digit paid subscribers, total revenue, and ad revenue growth in North America,” said David Gandler, co-founder and CEO of Fubo.

The company remains confident in its antitrust lawsuit against The Walt Disney Co (NYSE:DIS), FOX Corp (NASDAQ:FOX), and Warner Bros. Discovery Inc (NASDAQ:WBD) over a planned sports streaming joint venture. The ongoing investigation by the Department of Justice and congressional inquiries are also encouraging signs.

Outlook: FuboTV expects second-quarter revenue of $365.5 million – $376.5 million (versus consensus of $355.23 million) and fiscal 2024 revenue of $1.558 billion -$1.580 billion (prior $1.536 billion – $1.560 billion) versus consensus of $1.560 billion.

FUBO stock gained 34% in the last 12 months. Investors can gain exposure to the stock via ProShares Trust ProShares Metaverse ETF  (NYSE:VERS) and IShares Robotics And Artificial Intelligence Multisector ETF (NYSE:IRBO).

Price Action: FUBO shares gave up the premarket gains and are down 5.16% at $1.46 at the last check Friday.

Photo: courtesy of FuboTv.

Total
0
Shares
Related Posts
Read More

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

PAYS

Read More

The FDA has Cleared Vertex Pharmaceuticals’ Investigational New Drug Application For VX-264, Stem Cell-Derived Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into Vertex-Developed, Immunoprotective Device For Type 1 Diabetes

Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2023 to study the safety, tolerability and efficacy of VX-264 in patients with T1D. The company previously received approval from Health Canada

VRTX